Martin Shkreli violated lifetime pharma industry ban, FTC and states say in contempt claim — Live Feedhttps://www.live-feeds.com/feed/martin-shkreli-violated-lifetime-pharma-industry-ban-ftc-and-states-say-in-contempt-claimContinuously updated, source-cited coverage. FTC and States Accuse Martin Shkreli of Violating Pharma Banhttps://www.live-feeds.com/feed/martin-shkreli-violated-lifetime-pharma-industry-ban-ftc-and-states-say-in-contempt-claimhttps://www.live-feeds.com/feed/martin-shkreli-violated-lifetime-pharma-industry-ban-ftc-and-states-say-in-contempt-claim#u125660Fri, 16 Oct 2026 11:00:20 +0000Federal and state regulators are moving to hold Martin Shkreli in contempt for allegedly violating a lifetime ban from the pharmaceutical industry. The Federal Trade Commission and seven states claim Shkreli breached the restriction by trading drug stocks and providing market commentary that influenced biopharma equities. Regulators are asking a judge to find him in contempt and are demanding that he divest his pharmaceutical holdings. The fresh legal action places the controversial executive back in the sights of authorities following previous federal enforcement actions.Why it mattersThe con